Review| Volume 58, ISSUE 2, P135-138, February 2020

Oral tyrosine kinase inhibitors in OMFS: a review

Published:January 16, 2020DOI:


      It is increasingly common in OMFS to treat patients who are taking therapeutic doses of anticoagulant or antiplatelet drugs, or both. These patients have a high risk of postoperative bleeding ranging from minor oozing that can be managed using local measures, to a major haemorrhage necessitating transfusion. The risk of bleeding associated with tyrosine kinase inhibitors (TKI) taken orally is not well-known in the specialty. We report a case series of two patients treated with them and discuss this group of drugs.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jeong W.
        • Doroshow J.H.
        • Kummar S.
        United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.
        Curr Probl Cancer. 2013; 37: 110-144
        • Parmar S.
        • Patel K.
        • Pinilla-Ibarz J.
        Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.
        P T. 2014; 39: 483-519
        • Johnstone N.
        • Jadhav S.
        • Subramanian G.
        Guideline for patients on antiplatelet agents undergoing elective, non-cardiac surgical intervention.
        2018 (Available from URL: (last accessed 16 November 2019))
        • Foster A.
        • Dasgupta Dr.
        Oral anticoagulants (VKA and NOAC): guidelines for prescribing, monitoring and management.
        Wirral Clinical Commissioning Group, 2015 (Available from URL: (last accessed 16 November 2019))
      1. Lancashire and South Cumbria Medicines Management Group. Low molecular weight heparins (LMWHs): summary prescribing guide. Available from URL: (last accessed 16 November 2019).

        • Solari F.
        • Varacallo M.
        Low molecular weight heparin (LMWH) (updated February 2019).
        StatPearls Publishing, 2019 (Available from URL: (last accessed 19 November 2019))
        • Hirsh J.
        • Anand S.S.
        • Halperin J.L.
        • et al.
        Mechanism of action and pharmacology of unfractionated heparin.
        Arterioscler Thromb Vasc Biol. 2001; 21: 1094-1096
        • National Institute for Health and Care Excellence
        British National Formulary (BNF) May, 2019 (Available from URL: (last accessed 19 November 2019))
        • Barts Health NHS Trust
        Guideline on selecting appropriate non-vitamin K antagonist oral anticoagulants (NOACs)/direct oral anticoagulants (DOACs).
        2016 (Available from URL: (last accessed 19 November 2019))
        • National Institute for Health and Care Excellence
        British National Formulary (BNF) May, 2019 (Available from URL: (last accessed 16 November 2019))
        • Hansen C.R.
        • Grimm D.
        • Bauer J.
        • et al.
        Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma.
        Int J Mol Sci. 2017; 18: 461
        • Fujihara S.
        • Mori H.
        • Kobara H.
        • et al.
        Uncommon gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a report of four cases.
        Oncol Lett. 2015; 10: 2895-2898
        • Schwandt A.
        • Wood L.S.
        • Rini B.
        • et al.
        Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.
        Onco Targets Ther. 2009; 2: 51-61
        • Brown J.R.
        How I treat CLL patients with ibrutinib.
        Blood. 2018; 131: 379-386
        • Jaglowski S.M.
        • Jones J.A.
        • Flynn J.M.
        • et al.
        A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and of atumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
        J Clin Oncol. 2012; 30 (Available from URL: (last accessed 25 November 2019)): 6508
        • Jones J.A.
        • Hillmen P.
        • Coutre S.
        • et al.
        Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
        Br J Haematol. 2017; 178: 286-291
        • O’Brien S.
        • Jones J.A.
        • Coutre S.E.
        • et al.
        Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
        Lancet Oncol. 2016; 17: 1409-1418